John Oyler Sells 16,581 Shares of BeiGene, Ltd. (BGNE) Stock
BeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler sold 16,581 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $86.76, for a total value of $1,438,567.56. Following the completion of the transaction, the chief executive officer now directly owns 332,697 shares of the company’s stock, valued at approximately $28,864,791.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
John Oyler also recently made the following trade(s):
- On Wednesday, November 29th, John Oyler sold 85,906 shares of BeiGene stock. The stock was sold at an average price of $84.66, for a total value of $7,272,801.96.
- On Monday, November 13th, John Oyler sold 25,054 shares of BeiGene stock. The stock was sold at an average price of $83.06, for a total value of $2,080,985.24.
- On Wednesday, November 15th, John Oyler sold 150,957 shares of BeiGene stock. The stock was sold at an average price of $80.50, for a total value of $12,152,038.50.
Shares of BeiGene, Ltd. (NASDAQ:BGNE) opened at $80.00 on Friday. BeiGene, Ltd. has a 52 week low of $26.43 and a 52 week high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20.
BeiGene (NASDAQ:BGNE) last released its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same quarter last year, the business earned ($1.08) earnings per share. research analysts expect that BeiGene, Ltd. will post -3.09 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in BGNE. Hillhouse Capital Management Ltd. boosted its stake in BeiGene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock worth $167,433,000 after purchasing an additional 2,355,906 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in BeiGene in the third quarter worth $62,076,000. Janus Henderson Group PLC purchased a new position in BeiGene in the third quarter worth $33,744,000. Alliancebernstein L.P. purchased a new position in BeiGene in the second quarter worth $7,373,000. Finally, Employees Retirement System of Texas purchased a new position in shares of BeiGene in the second quarter valued at $2,855,000. Institutional investors own 55.33% of the company’s stock.
A number of analysts have commented on BGNE shares. Maxim Group set a $120.00 price target on shares of BeiGene and gave the company a “buy” rating in a research report on Tuesday, November 14th. Cowen restated a “buy” rating on shares of BeiGene in a research note on Tuesday, November 14th. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 price objective (up from $58.00) on shares of BeiGene in a report on Tuesday, November 14th. Zacks Investment Research downgraded shares of BeiGene from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $87.00) on shares of BeiGene in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $96.67.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.